Psychedelics as a treatment for disorders of consciousness
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Based on its ability to increase brain complexity, a seemingly reliable index of conscious level, we propose testing the capacity of the classic psychedelic, psilocybin, to increase conscious awareness in patients with disorders of consciousness. We also confront the considerable ethical and practical challenges this proposal must address, if this hypothesis is to be directly assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Detecting awareness in the vegetative state
Owen, A. M., Coleman, M. R., Boly, M., Davis, M. H., Laureys, S., & Pickard, J. D. (2006) · Science · doi:10.1126/science.1130197 · Cited by 1,978
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“The physiological safety of 30mg/70kg psilocybin has been well-demonstrated in healthy volunteers (Griffiths et al. 2006).”
Tononi, G., Sporns, O., & Edelman, G. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.11.5033 · Cited by 1,626 · cited 2×
“Tononi and Edelman posited that during conscious awareness, ‘heterogeneous patterns of short-term correlations within the corticothalamic system will result in [high neural complexity]’ (Tononi et al. 1994).”
BackgroundCarhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 2×
“In our Phase 2 study in treatment-resistant depression, psychologically supported administration of oral psilocybin (10–25 mg) was well-tolerated by all patients, with the most common adverse events being mild transient anxiety just prior to as well as during drug onset (Carhart-Harris et al. 2016).”
BackgroundSelf-citationA theoretically based index of consciousness independent of sensory processing and behavior
Casali, A. G., Gosseries, O., Rosanova, M., Boly, M., Sarasso, S., Casali, K. R., Casarotto, S., Bruno, M.-A., Laureys, S., Tononi, G., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006294 · Cited by 1,246 · cited 9×
“A range of therapies have been proposed for patients with DoC, including pharmacological (e.g. zolpidem, amantadine) (Gosseries et al. 2014), invasive- [e.g. deep brain stimulation (DBS) (Vanhoecke and Hariz 2017), vagal nerve stimulation (VNS) (Corazzol et al. 2017)] and non-invasive electrical stimulation [e.g. tran…”
BackgroundInfluentialPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Self-citationThe Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future
Carhart-Harris, R. L., & Goodwin, G. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.84 · Cited by 706
Self-citationPsychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 9×
“Psilocybin elevates measures of brain complexity in healthy humans (Schartner et al. 2017a; Carhart-Harris 2018) and many other lines of evidence support the idea that psilocybin could elevate conscious awareness in patients with DoC.”
BackgroundMethodInfluentialSelf-citationSitt, J. D., King, J.-R., El Karoui, I., Rohaut, B., Faugeras, F., Gramfort, A., Cohen, L., Sigman, M., Dehaene, S., & Naccache, L. (2014) · Brain · doi:10.1093/brain/awu141 · Cited by 608 · cited 1×
“…[e.g. deep brain stimulation (DBS) (Vanhoecke and Hariz 2017), vagal nerve stimulation (VNS) (Corazzol et al. 2017)] and non-invasive electrical stimulation [e.g. transcranial direct current stimulation (Thibaut et al. 2014)], and transcranial magnetic stimulation (TMS) (Pistoia et al. 2013).”
Cited by
Temporal circuit of macroscale dynamic brain activity supports human consciousness
Huang, Z., Zhang, J., Wu, J., Mashour, G. A., & Hudetz, A. G. (2020) · Science Advances · doi:10.1126/sciadv.aaz0087 · Cited by 217
“Prior studies have reported global hyperconnectivity of fMRI signals in schizophrenic patients (34), as well as shared phenomenology between schizophrenic symptoms and ketamine’s dissociative/ psychoactive effects (30, 32).”
BackgroundPharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review
van Elk, M., & Yaden, D. B. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104793 · Cited by 221
Dimensions of consciousness and the psychedelic state
Bayne, T., & Carter, O. (2018) · Neuroscience of Consciousness · doi:10.1093/nc/niy008 · Cited by 142
Functional geometry of the cortex encodes dimensions of consciousness
Huang, Z., Mashour, G. A., & Hudetz, A. G. (2023) · Nature Communications · doi:10.1038/s41467-022-35764-7 · Cited by 101
Measuring Consciousness in the Intensive Care Unit
Edlow, B. L., Fecchio, M., Bodien, Y. G., Comanducci, A., Rosanova, M., Casarotto, S., Young, M. J., Li, J., Dougherty, D. D., Koch, C., et al. (2023) · Neurocritical Care · doi:10.1007/s12028-023-01706-4 · Cited by 50
“Additional applications in future clinical trials include the use of TMS-EEG to predict individualized responses to therapies [69], and to measure subclinical therapeutic responses [70].”
Method
Metadata
- Authors
- Scott, G., & Carhart-Harris, R. L.
- Venue
- Neuroscience of Consciousness
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-01-01
- Volume
- 2019
- Issue
- 1
- Pages
- niz003-niz003
- ISSN
- 2057-2107 (ISSN-L)
- OpenAlex
- W2938595859
- Cited by
- 74
- References
- 30
- FWCI
- 7.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Psychedelics as a treatment for disorders of consciousness. https://app.cochat.ai/papers/10.1093/nc/niz003
- The paper
- Scott, G., & Carhart-Harris, R. L. (2019). Psychedelics as a treatment for disorders of consciousness. Neuroscience of Consciousness. https://doi.org/10.1093/nc/niz003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.